The continuous glucose monitor being developed for people with Type 2 diabetes who don’t take insulin could open up the CGM market to 25 million people in the U.S., the company’s new chief commercial officer said.
The continuous glucose monitor being developed for people with Type 2 diabetes who don’t take insulin could open up the CGM market to 25 million people in the U.S., the company’s new chief commercial officer said.